Accellab is a one-stop integrated CRO dedicated to the preclinical assessment of medical devices under GLP compliance. Specialized in the fields of interventional cardiology, orthopedics, dental medicine, spine, neurology, gastroenterology, ENT, sports and regenerative medicine, our research center conducts safety and efficacy preclinical studies at its Boisbriand site located in the greater Montreal area, Canada.
Accellab exercises a leadership role coordinating medical device preclinical services and offering an integrated approach to medical device studies with a commitment to scientific excellence, an appreciation of client-specific, and an understanding of regulatory considerations.
Company Details
- Employees
- 40
- Founded
- -
- Address
- 1635 Lionel-Bertrand Blvd., Boisbriand,quebec J7h 1n8,canada
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- https://accellab.com/
- Keywords
- Medical Devices, Regulatory Testing, Interventional Cardiology, Orthopedics, Spine, Dental Medicine, ENT, Regenerative Medicine, Preclinical Testing, GLP, Histology, Histopathology, Histomorphometry, Imaging, Safety testing, Efficacy testing, Performance testing, Gastroenterology, Sports Medicine, Neurology, Oncology.
- HQ
- Boisbriand, Quebec
Accellab Questions
Accellab's website is https://accellab.com/
Accellab's LinkedIn profile is https://ca.linkedin.com/company/accellab
Accellab has
40 employees.
View email and phone details for 40
employees at Accellab.
Accellab's industry is
Research Services
Accellab's top competitors are
Altasciences,
Charles River Laboratories,
Citoxlab, A Charles River Company,
Axcell Labs,
Biodextris,
Indero (Formerly Innovaderm),
Stagebio,
Neopharm Labs,
Puzzle Medical Devices® Inc.,
Anges Québec.
Accellab's categories are Research Services
Accellab's founding year is 2024
